脫氫表雄酮 DHEA × 更年期

結論:主流反證據

The engine claim concerns the ORAL DHEA supplement for menopause, and for that specific product the evidence is weak-to-null.

D 🔴 D 反證據 主流反證據 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 ⚠️ COI(產業聯盟資助) 🇹🇼 台灣在地警示

The engine claim concerns the ORAL DHEA supplement for menopause, and for that specific product the evidence is weak-to-null. A 2014 systematic review of 23 RCTs in 1188 postmenopausal women found no significant improvement in libido or sexual function (SMD 0.35, 95% CI -0.02 to 0.73, P=0.06) and no benefit on lipids, glucose, weight, BMI, or bone density; a 2025 meta-analysis confirms oral DHEA raises testosterone and estradiol blood levels only at >=50 mg/day but the estradiol rise (~7.86 pg/mL) is likely clinically minimal and symptoms/quality of life were not improved per a cited Cochrane review. Examine grades all hard clinical menopausal endpoints (Libido, Subjective Well-Being, Sleep Quality) only D 'No effect' from single 50-participant studies, with B grades reserved for surrogate hormone markers. NCCIH, Mayo, Cleveland Clinic, Harvard, and The Menopause Society all draw the same route-dependent line: oral DHEA is not shown to help menopausal symptoms or libido and is not recommended, while intravaginal DHEA (prasterone/Intrarosa) is a separate FDA-approved DRUG with genuine RCT evidence for genitourinary syndrome dyspareunia. Because the supplement claim has no proven clinical benefit on general menopausal symptoms and the only real evidence belongs to a different product and route, an honest grade for the ORAL supplement is D.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.39
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 主流反證據
信心度
79%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.30
L11 AI 複核獨立判讀
0.30
L5 臨床機構權威立場
0.40
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.387
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

The Benefits and Harms of Systemic Dehydroepiandrosterone (DHEA) in Postmenopausal Women With Normal Adrenal Function: A Systematic Review and Meta-analysis
PMID: 25279571 2014 統合分析 n = 1,188
結論:Systemic DHEA was NOT associated with significant improvement in libido or sexual function (SMD 0.35, 95% CI -0.02 to 0.73, P=0.06, I2=62%). No significant effect on serious adverse effects, serum lipids, serum glucose, weight, BMI, or bone mineral density. Authors concluded low-confidence evidence shows systemic DHEA does not significantly impact sexual symptoms or selected metabolic markers in postmenopausal women with normal adrenal function.
效應量:SMD sexual function 0.35 (95% CI -0.02 to 0.73), non-significant
前往 PubMed
Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects
PMID: 40616152 2025 統合分析 n = 1,084
結論:Oral DHEA significantly increased testosterone (WMD 24.31 ng/dL, 95% CI 15.22-33.40, P<=0.001) and estradiol (WMD 7.86 pg/mL, 95% CI 6.33-9.40, P<=0.001). Effect seen only at >=50 mg/day; doses <50 mg/day had no significant effect. Authors cautioned the 7.86 pg/mL estradiol rise may be clinically minimal, and noted a referenced Cochrane review found DHEA did not significantly improve quality of life or menopausal symptoms.
🟠 品質有限 效應量:WMD testosterone +24.31 ng/dL; estradiol +7.86 pg/mL (hormone levels only, not symptoms)
前往 PubMed
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause
PMID: 30358731 2018 RCT (double-blind) n = 482
結論:Intravaginal prasterone significantly improved all four FDA co-primary endpoints: dyspareunia decreased 0.36 severity unit over placebo (P=0.0002); vaginal dryness decreased 0.27 unit over placebo (P=0.004); parabasal cells decreased 27.7% vs placebo (P<0.0001); superficial cells increased 8.44% vs placebo (P<0.0001); vaginal pH decreased 0.66 units (P<0.0001). NOTE: this is the FDA-approved intravaginal DRUG (Intrarosa), not the oral supplement.
⚠️ 廠商資助 效應量:Dyspareunia -0.36 severity unit over placebo (P=0.0002)
前往 PubMed
Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase
PMID: 30244783 2018 系統性回顧
結論:All RCTs of vaginal DHEA in vulvovaginal atrophy showed sexual dysfunction improved with treatment; vaginal DHEA was superior to placebo and at least as efficacious as vaginal estrogens. Concluded intravaginal DHEA appears safe and effective for menopausal vulvovaginal atrophy and dyspareunia. NOTE: applies to the intravaginal drug route, not oral DHEA supplements.
效應量:Qualitative; consistent improvement vs placebo across included RCTs
前往 PubMed

L4a US FDA
謹慎
Intrarosa (prasterone) is the first FDA-approved product containing the active ingredient prasterone, also known as dehydroepiandrosterone (DHEA). 來源↗
L4b EU EFSA
反對
L4c UK NHS
反對
DHEA is classed as a prescription-only medicine in the UK and is also a Class C controlled drug. 來源↗
L4d TW TFDA / 衛福部
反對
DHEA(脫氫表雄酮)在台灣屬於藥品列管,不論劑量高低均以藥品管理,須由醫師開立處方;不得作為食品或膳食補充劑販售。 來源↗
L4e WHO
謹慎
DHEA is included in the pharmacological class S1 'Anabolic Agents' as an Anabolic Androgenic Steroid, prohibited at all times (in and out of competition) under the World Anti-Doping Code. 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
謹慎
DHEA can help improve symptoms of vaginal atrophy when treatment is given through the vagina. 來源↗
L5c Cleveland Clinic
謹慎
L5d Harvard Health
謹慎
L5e Specialty Society (condition-mapped)
謹慎

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群對 DHEA 的原生討論幾乎集中在備孕/卵巢早衰(PTT GoodPregnan 版),用於『更年期』的真實實測極少:僅見 PTT elderly 版一篇『減緩更年期症狀』提問,少數推文稱長輩吃了較好睡、情緒較開朗,但隨即被質疑推文 IP 相似(疑似帶帳號業配)。更年期角度的 SERP 多被電商(亞尼活力、赫而司、長松)與健康媒體 SEO 文佔據,社群原生口碑稀薄。整體屬反應分歧且業配污染重,非研究級證據。

💬社群實感

分歧/更年期向心得稀少(僅零星正面分享情緒與睡眠改善,且疑似業配,社群原生實測不足以判定)

破解迷思 社群最常見的 4 個誤解
事實把 DHEA 當成『純天然抗老青春荷爾蒙』而忽略其為類固醇前驅物、有雄性化與荷爾蒙敏感腫瘤風險
事實誤以為山藥/薯蕷皂素膠囊(diosgenin)人體可自行轉成 DHEA(實際上人體無此轉化途徑,需直接補充 DHEA)
事實劑量越高越有效(實為過量反致雄性化副作用,且乳癌/卵巢/攝護腺癌族群應避免)
事實把更年期所有不適一律歸因荷爾蒙下降而自行補 DHEA(可能掩蓋失智、甲狀腺或精神疾病等其他病因)
🩹 社群通報的副作用
  • 冒痘 / 皮膚出油
  • 體毛增加
  • 落髮
  • 亂經 / 經期提前(多來自備孕版使用者反饋)
  • 聲音低沉等雄性化徵象(多為說明書與藥師文,非更年期實測)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 赫而司(山藥薯蕷皂素/DHEA 配方)
  • 長松(DHEA 青春之泉)
  • 亞尼活力(山藥薯蕷膠囊,備孕社群聲量最大,外溢至更年期)
  • 賜汝蒙 Sterone(DHEA,多見於備孕版)
  • 特補樂
  • 益富 / 益力壯(女性全營養配方,elderly 版偶見)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

脫氫表雄酮(DHEA)不分劑量都視為藥品

代表來源 ↗
L10b · TFDA 法定身份 官方認定

脫氫表雄酮(DHEA)不分劑量都視為藥品

來源 ↗

  • 停經期荷爾蒙治療(MHT)
  • 陰道局部雌激素(治療泌尿生殖症候群)
  • 生活型態調整(規律運動、體重管理、戒菸)
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v25 engine_version: v1.0 claim_id: CLM-COND-menopause-INT-dehydroepiandrosterone-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-menopause-INT-dehydroepiandrosterone-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "脫氫表雄酮能改善更年期",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 1,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🔴 D 反證據"
  }
}